Kratom In Supplements Reaches Dead End On DEA Direct Regulatory Path
This article was originally published in The Rose Sheet
DEA says more kratom was seized from US firms in the first half of 2016 than in any previous year, but the seizures came two years after FDA imposed an import alert to stop shipments and three years after the agency stumbled out of the gate in determining whether the ingredient could be used in supplements.
You may also be interested in...
US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change
HHS released to industry proponents Reps. Mark Pocan and Morgan Griffith the letter it submitted in 2018 notifying DEA that it was rescinding recommendation it made in 2017 to list kratom active ingredients mitragynine and 7-hydroxymitragynine under Schedule I of the CSA.
Controversy Brews With 'Inaccurate' Reports Linking Kratom To Deaths
American Kratom Association and independent researchers explain the ingredient's history of safe use in a media briefing. Medical examiners "have tried to pin on kratom" the recent deaths of men in Florida and New York, says trade group Chairman Dave Herman.
DEA Takes Comments On Kratom, But Keeps Eye On Scheduling
DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.